Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide.
Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance.
Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.
-
Industrie
-
Biotechnology Research
-
Größe des Unternehmens
-
51-200 Mitarbeiter
-
Hauptsitz
-
Cambridge, Cambridgeshire
-
Typ
-
In Privatbesitz
-
Gegründet
-
2014
-
Spezialitäten
-
Clinical genetics, Whole Genome Sequencing, Next Generation Sequencing, Genetic Variation Analysis, Rare diseases, Genomics, Digital Health, and Empowering Healthcare
